Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Pavord, Ian; Chanez, Pascal; J. Criner, Gerard; A.M. Kerstjens, Huib; Korn, Stephanie; Lugogo, Njira; Martinot, Jean‐Benoît; Sagara, Hironori; C. Albers, Frank; Bradford, Eric; Harris, Stephanie; Mayer, Bhabita; Rubin, David; W. Yancey, Steven; C. Sciurba, Frank

doi:10.1056/nejmoa1708208

Public

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Published in New England Journal of Medicine • Sep 12, 2017

Authors:

Ian Pavord

Pascal Chanez

Gerard J. Criner

Abstract

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5. METHODS: We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group tri...

Subject

Mepolizumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!